Chemo-immunotherapy as first-line treatment for small-cell lung cancer. [Review] (Record no. 6118)

MARC details
000 -LEADER
fixed length control field 02474nam a22003497a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 210217s20202020 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1758-8340
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1177_1758835920980365 [pii]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1177/1758835920980365 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC7750570 [pmc]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 33414848
245 ## - TITLE STATEMENT
Title Chemo-immunotherapy as first-line treatment for small-cell lung cancer. [Review]
251 ## - Source
Source Therapeutic Advances in Medical Oncology. 12:1758835920980365, 2020.
252 ## - Abbreviated Source
Abbreviated source Ther Adv Med Oncol. 12:1758835920980365, 2020.
253 ## - Journal Name
Journal name Therapeutic advances in medical oncology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2020
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2021
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status epublish
266 ## - Date added to catalog
Date added to catalog 2021-02-17
520 ## - SUMMARY, ETC.
Abstract Small-cell lung cancer (SCLC) is a highly lethal subtype of lung cancer. Despite concerted efforts over the past several decades, there have been limited therapeutic advances. Traditional chemotherapy offers a high response rate and rapid symptomatic improvement, but its benefit is fleeting, and relapse is quick and unforgiving. Immunotherapy has delivered improved outcomes for patients with many cancers and there was compelling rationale for development in SCLC. While initial efforts with cytotoxic T-lymphocyte protein-4 inhibitors failed to improve upon chemotherapy alone, the addition of programmed death ligand-1 (PD-L1) inhibitors to first-line chemotherapy finally provided long-awaited gains in survival. Atezolizumab, when added to carboplatin and etoposide, improved both progression-free survival and overall survival. Durvalumab, when added to platinum plus etoposide, similarly improved OS. Biomarker development has stalled as PD-L1 expression and tumor mutational burden have not been useful predictive biomarkers. However, based on the significant survival improvements, both atezolizumab and durvalumab were approved by the US Food and Drug Administration to be given with first-line chemotherapy, and these regimens represent the new standards of care for SCLC. Copyright (c) The Author(s), 2020.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Medicine/General Internal Medicine
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Review
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Farid, Saira
790 ## - Authors
All authors Farid S, Liu SV
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1177/1758835920980365">https://dx.doi.org/10.1177/1758835920980365</a>
Public note https://dx.doi.org/10.1177/1758835920980365
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 02/17/2021   33414848 33414848 02/17/2021 02/17/2021 Journal Article

Powered by Koha